Abstract: A nanocomplex, 50 to 1000 nm in size, containing a lipid-like nanoparticle formed of a cationic lipid-based compound and a modified protein formed of a protein and an anionic polymer that includes a plurality of polar groups, the lipid-like nanoparticle and the modified protein being non-covalently bonded to each other. Also disclosed are a method of preparing the above-described nanocomplex and use thereof for treating a medical condition. Further disclosed is a pharmaceutical composition containing a nanocomplex.
Abstract: A composition-of-matter is provided. The present composition includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and cognition, dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities and/or dietary supplements capable of increasing alcohol catabolism and decreasing the level of toxic products of alcohol catabolism.
Abstract: Semisolid oral dispersions for whitening teeth. The semisolid oral dispersions include hydrophilic bleaching agent particles in a hydrophobic phase. The hydrophilic bleaching agent particles can include peroxide compounds and/or hydrogen peroxide adducts. The hydrophilic bleaching agent particle can have a solubility in water of at least about 20 parts, by weight of the particles, in about 100 parts, by weight, of water.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
January 18, 2022
Assignee:
The Procter & Gamble Company
Inventors:
Paul Albert Sagel, Jayanth Rajaiah, Michael David Curtis
Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.
Type:
Grant
Filed:
February 18, 2020
Date of Patent:
December 28, 2021
Assignee:
Indiana University Research and Technology Corporation
Inventors:
Jeffrey A. Kline, Nathan J. Alves, Daren M. Beam
Abstract: In various embodiments functionalized graphene oxide(s) are provided that demonstrate improved antimicrobial activity, where the graphene oxide(s) are functionalized to increase carbon radical (.C) density.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
December 28, 2021
Assignees:
The Regents of the University of California, Northwestern University
Inventors:
Andre E. Nel, Tian Xia, Ruibin Li, Mark C. Hersam, Nikhita D. Mansukhani, Linda Guiney
Abstract: Provided herein are methods and composition for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle ear for rapid, localized treatment and prevention of diseases and conditions associated with a middle ear infection. In particular, provided herein are cationic, anionic, and polymer-based nanoparticles that provide a platform for delivery of therapeutic cargo, as well as cationic, anionic, and polymer-based nanoparticles compositions for rapid, localized delivery of therapeutic agents to the middle ear.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
December 14, 2021
Assignee:
The Medical College of Wisconsin, Inc.
Inventors:
Amit Joshi, Joseph Edward Kerschner, Wenzhou Hong, Gayatri Sharma
Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
Type:
Grant
Filed:
November 23, 2016
Date of Patent:
December 7, 2021
Assignee:
The Regents of the University of California
Inventors:
Samir Mitragotri, Marta Broto, Kathryn M. Camacho, Stefano Menegatti
Abstract: A mouth rinse composition with a cationic antimicrobial agent and an anti-stain agent, which is a functionalized polyethylene glycol. A dentifrice composition with a cationic antimicrobial agent and an anti-stain agent, which is a functionalized polyethylene glycol. The cationic antimicrobial agent is a quaternary ammonium salt, such as cetyl pyridinium chloride, or a metal ion source, such as stannous fluoride.
Abstract: Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.
Abstract: Disclosed is a system and method for the delivery, into interdental spaces, of oral care active agents contained in particles. The particles are made of one or more superabsorbent polymers (SAP), and are of size generally small enough to be easily applied into an interdental space. To this end, the particles typically have a length of below 1.5 mm. By virtue of the SAP's ability of absorbing several times its own weight in water, the particles will swell once in contact with saliva. As a result, the volume of the particles as applied in between teeth increases by at least eight times, thereby effectively making the particles larger than the average interdental gap size. The particles, once swollen, are thus held more firmly between the walls of the interdental space, thus preventing them from being easily washed away.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
November 30, 2021
Assignee:
KONINKLIJKE PHILIPS N.V.
Inventors:
Maaike Cornelia Johanna Wilhelmina Van Hulten, Bart Gottenbos, Carl Glasse
Abstract: Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
November 23, 2021
Assignee:
VERILY LIFE SCIENCES LLC
Inventors:
Kimberly Kam, Zhan Wang, Stephen Morton, Nicole Peck
Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
Type:
Grant
Filed:
February 26, 2017
Date of Patent:
November 23, 2021
Assignee:
NOBIO LTD.
Inventors:
Nathan Zaltsman, Ervin I. Weiss, Nurit Beyth
Abstract: The present invention discloses stimuli-sensitive protein conjugate which can make supramolecular protein assemblies and methods for using the same. The present invention provides simple and rational process for construction of said stimuli-sensitive spherical protein assemblies through supramolecular chemical strategy.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
November 16, 2021
Assignee:
Indian Institute of Science Education and Research
Abstract: Metal oxide powder formed of metal oxide particles, in which the metal oxide powder has first metal oxide particles having at least one protrusion portion and second metal oxide particles, the first metal oxide particles have an average primary particle diameter of 100 nm or more and 1,000 nm or less, the second metal oxide particles have an average primary particle diameter of less than 100 nm, and a fraction of a total mass of particles having a primary particle diameter of less than 100 nm in a total mass of the metal oxide powder is 0.3% by mass or more and 10% by mass or less.
Abstract: A method of encapsulating an active comprising preparing a first mixture comprising the active, a compound that functions as a Michael donor, and a compound that functions as a Michael acceptor, preparing a second mixture comprising water and an emulsifier; preparing a reaction mixture by combining the first mixture, the second mixture, and a compound that functions as a Michael catalyst; agitating the reaction mixture; wherein the active has a water solubility of at most 0.5% (w/w) at 25° C.
Abstract: An improved hair and scalp treatment composition comprising a hair care product wherein the improvement comprises reducing the comedogenicity thereof by excluding therefrom comedogenic elements having a Fulton scale grade greater than 2.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
November 2, 2021
Assignee:
CLARITY COSMETICS INC.
Inventors:
Iris Rubin, Gregory Maged, John Garruto, Bethany McCarver
Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
October 19, 2021
Assignees:
Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
Inventors:
Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
October 12, 2021
Assignee:
Infectious Disease Research Institute
Inventors:
Christopher B. Fox, Amit Praful Khandhar, Neal Van Hoeven, Jesse H. Erasmus, Susan S. Lin
Abstract: Chitosan-coated, flexible lipid-based nanoparticles are provided. The nanoparticles (“chitoplexes”) comprise an interior comprising a mixture of a phospholipid, an edge activator, a charge inducing agent, and a statin; and an exterior chitosan coating which encapsulates the interior mixture. The chitoplexes exhibit enhanced bioavailability with respect to delivering the statins encapsulated therein to a subject, for example, for the treatment of cancer.